David Cicilline

It is unacceptable. The United States stands alone as the only Nation that sentences people to life without parole for crimes committed before turning 18.

Of course, Rhode Island is the offshore wind capital of America.

We will never have a greater responsibility than to do all that we can to expose crimes against humanity and genocide.

I think that regulatory reform and competition advocacy are very, very important.

I think these are good initiatives. They're really a top-down, not bottom-up approach.

I am supportive of doing something. I am actually not against this bill, but I think it's a piecemeal approach.

Today, pharmaceutical companies are confronting the American people with a terrible choice: Miss rent payments and skip meals to pay for their prescriptions or go without the lifesaving medications that they need.

I look forward to joining Mr. Issa in reforming our Nation's patent laws.

To explicitly prohibit healthcare mergers that enable greater exploitation of existing market power and are likely to result in harm to consumers.

I am also pleased to be in partnership with Representatives Johnson and Issa in a House companion to a bill.

Break them up. That is the remedy that I have advocated on some of the Big Tech companies.

We need to get that done immediately. That will add significant resources to the two agencies, plus the appropriations policy.

You can't just do that and expect these healthcare pharma issues to be taken care of without funding those agencies.

It is outrageous that we still have this practice going on where pharmaceuticals are paying their competitors to keep their products off the market.

I also have worked on that bill with Senator Grassley.

First, I would suggest negotiation of drug prices under Medicare, a bill that I lead with Representative Welch.

I want to thank Senators Grassley, Cornyn, and Klobuchar, and Blumenthal for their work on these important issues.

This legislation addresses product hopping, a particular abusive form of conduct used by drug manufacturers to extend their monopolies.

Both parties here are looking for effective public action to guarantee real market competition.

It is unacceptable that hundreds of thousands of cancer patients are reportedly delaying lifesaving care.

This is not true innovation, and it is costing hardworking Americans.

I am tremendously encouraged to see bipartisan efforts to address these critical needs and to help improve access to affordable prescription drugs for patients.

Product hopping causes patients to overpay by potentially billions of dollars annually for their prescription drugs.

It would eliminate the abuses of product hopping.

It is unacceptable that many seniors cannot afford the arthritis medication they need to perform everyday tasks.